TransMedics lifts annual sales forecast to $764m–$774m, including PAD Aviation
The organ-transplant technology group posted third-quarter sales of $203.0m and net income of $17.1m, and announced US regulatory clearances for trials plus an Italian tender win.
TransMedics Group now expects 2026 revenue of between $764m and $774m, a higher range than it gave before, the company said as it reported third-quarter results on 5 November. It said the new range takes PAD Aviation into account.
Third-quarter revenue came to $203.0m, which the company described as 41% higher than a year earlier. Net income for the quarter was $17.1m. The material available does not break revenue down by product, service or region.
The company also reported progress on the regulatory front. In October the US Food and Drug Administration approved investigational device exemptions for two studies, OCS ENHANCE Heart Part B and DENOVO Lung. Such exemptions let a device be used in a clinical study so that safety and effectiveness data can be gathered for a later marketing application. The agency also approved a continued access protocol for the ENHANCE Heart trial.
Separately, TransMedics said it had won its first transplant logistics tender in Europe, in Italy. Details of the trial designs, the tender's terms and any timelines were not available, so the commercial weight of these announcements cannot yet be judged.
Why it matters
- The guidance range of $764m–$774m, with PAD Aviation included, gives the market a concrete full-year revenue marker for the company.
- Two newly approved US trials, OCS ENHANCE Heart Part B and DENOVO Lung, point to continued clinical investment, though design and timing details were not disclosed.
- The Italian tender is the company's first logistics win in Europe. Its financial significance is unknown until contract terms are made public.
- Assessments should wait for the full results release and filings, since the available summary leaves out segment figures and trial specifics.
Company's press release (SEC filing): TransMedics Group, Inc. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
BeyondSpring wins FDA Fast Track for plinabulin-docetaxel in post-immunotherapy NSCLC as cash dwindles to $0.6M
Calidi cuts costs and restructures as Q3 loss reaches $3.6M ahead of CLD-401 IND
Beyond Air reports record $2.3M quarterly revenue as FDA reviews second-generation LungFit PH
DataMEDS AI Q3 revenue up 50% to $2.7M on GLP-1 dispensing
Curis reports Q3 loss of $8.1m as emavusertib trials enrol; cash runway reaches only early 2027
